Hsu YC, et al. - In patients with chronic hepatitis B continuously receiving NUC, researchers investigated the temporal change and determinants for the risk of HCC. A total of 65,426 infected patients receiving entecavir or tenofovir for at least 3 months were analyzed from the national healthcare database in Taiwan. Over time, a declining trend in the risk of HCC in patients with chronic hepatitis B receiving entecavir or tenofovir was observed. The risk of HCC was observed to be determined by cirrhosis, age, male sex, HCV coinfection, and diabetes.